Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01558661 · ClinicalTrials.gov registry record · Phase 2
Axitinib (AG-013736) in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
A Phase 2 study of Adenoid Cystic Carcinoma, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
- 1
- Study location
NCT01558661: Completed Phase 2 study of Adenoid Cystic Carcinoma, sponsored by Memorial Sloan Kettering Cancer Center.
NCT01558661 is a Phase 2 study of Adenoid Cystic Carcinoma that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 33 participants, below the 126-participant average among 16 other Adenoid Cystic Carcinoma trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01558661, a Phase 2 study of Adenoid Cystic Carcinoma, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to find out what effects, good and/or bad, a new treatment called axitinib has on the patient and adenoid cystic carcinoma. This type of cancer study is called a phase II study. Axitinib is an oral medication that can interfere with cancer cell growth and reduce the growth of blood vessels around tumors. This study will help find out if axitinib is a useful drug for treating patients with adenoid cystic carcinomas. Axitinib is an experimental drug that has not yet been approved by the Food and Drug Administration for use in adenoid cystic carcinoma.
Primary Outcome
Best overall response rate documented by RECIST v1.1 criteria of patients with progressive, recurrent/metastatic ACC treated with axitinib. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI and/or CT: Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD), neither sufficient shrinkage to qualify for a Partial Response nor sufficient increase to qualify for Progression of Disease
Conditions Studied
Interventions
- DRUG AG-013736 (AXITINIB)
Study Locations (1)
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2012-03 |
| Est. Completion | 2016-08 |
| Phase | Phase 2 |
What the finished NCT01558661 record still lists
NCT01558661 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 126-participant average among 16 other Adenoid Cystic Carcinoma trials with a reported enrollment target (74% lower).
The record links to 1 condition, with Adenoid Cystic Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which AG-013736 (AXITINIB) is the first listed.
NCT01558661 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT01558661 about?
NCT01558661 is a clinical study titled "Axitinib (AG-013736) in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma". The purpose of this study is to find out what effects, good and/or bad, a new treatment called axitinib has on the patient and adenoid cystic carcinoma. This type of cancer study is called a phase II study. Axitinib is an oral medication that can interfere with cancer cell growth and reduce the gro...
What is the current status of trial NCT01558661?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2012-03. Estimated completion is 2016-08.
What conditions does trial NCT01558661 study?
This clinical trial studies the following conditions: Adenoid Cystic Carcinoma.
What interventions are being tested in trial NCT01558661?
The interventions under investigation include: AG-013736 (AXITINIB) (DRUG).
Who is sponsoring clinical trial NCT01558661?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01558661 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Adenoid Cystic Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01558661's enrollment target sits among peer trials
33 13th of 16 higher than 3 of 16 other Adenoid Cystic Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Adenoid Cystic Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 2 Trial of Ivonescimab for Patients With Advanced, Metastatic Salivary Gland Cancers
RECRUITING · Phase 2
-
A Study of Enfortumab Vedotin in People With Adenoid Cystic Carcinoma
RECRUITING · Phase 2
-
9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma
ACTIVE NOT RECRUITING · Phase 2
-
Testing Lenvatinib in Patients With Adenoid Cystic Carcinoma
ACTIVE NOT RECRUITING · Phase 2
-
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
ACTIVE NOT RECRUITING · Phase 2
-
Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia